Effect of Intracoronary Infusion of Bone Marrow Mononuclear Cells or Peripheral Endothelial Progenitor Cells on Myocardial Ischemia-reperfusion Injury in Mini-swine

Li, Chongjian; Gao, Runlin; Yang, Yuejin; Hu, Fenghuan; Yang, Wei; Shang, You; Song, Li; Ruan, Yijun; Qiao, Shubin; Chen, Jilin; Li, Jianjun

doi:10.1016/s1001-9294(10)60044-2

Cited by 10 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is also important to note that it might not be appropriate to make comparisons between cell dosing studies that have used different routes of administration. Furthermore, although many preclinical studies [8][9][10][11] and clinical trials [12][13][14][15][16][17][18][19][20] have examined other cell types, such as bone marrow-derived mononuclear cells (BMMNCs), c-kit + cardiac stem cells, and cardiac CD105 + culture-expanded MSCs (cardiosphere-derived cells), they did not compare the cell doses but, rather, single doses with different cell products or placebo.…”

Section: Clinical Studiesmentioning

confidence: 99%

Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease

Golpanian

Schulman

Ebert

et al. 2015

Stem Cells Translational Medicine

120

View full text Add to dashboard Cite

An important stage in the development of any new therapeutic agent is establishment of the optimal dosage and route of administration. Inconsistent findings have been reported regarding the relationship between the cell dose and clinical benefit. The present study summarizes the data regarding the optimal cell dosage and route of administration from studies of stem cell therapy for heart disease and offers a perspective on future directions.

show abstract

Section: Clinical Studiesmentioning

confidence: 99%

Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease

Golpanian

Schulman

Ebert

et al. 2015

Stem Cells Translational Medicine

120

View full text Add to dashboard Cite

show abstract

“…Immunosuppression for MSCs might be redundant because these cells are considered by some to be immunoprivileged. 31 However, MSCs do interact with the immune system, play a role in immunomodulation, 32,33 and even elicit immune responses in vivo. 34 We performed a post hoc meta-regression of cell source for MSCs alone to establish whether there was any evidence of immune privileged properties for MSCs in cardiac repair.…”

Section: Autologous Versus Allogeneic Cell Therapymentioning

confidence: 99%

Similar Effect of Autologous and Allogeneic Cell Therapy for Ischemic Heart Disease

Eding

Vesterinen

Spoel

et al. 2015

Circulation Research

View full text Add to dashboard Cite

Rationale:In regenerative therapy for ischemic heart disease, use of both autologous and allogeneic stem cells has been investigated. Autologous cell can be applied without immunosuppression, but availability is restricted, and cells have been exposed to risk factors and aging. Allogeneic cell therapy enables preoperative production of potent cell lines and immediate availability of cell products, allowing off-the-shelf therapy. It is unknown which cell source is preferred with regard to improving cardiac function.Objective: We performed a meta-analysis of preclinical data of cell therapy for ischemic heart disease. Methods and Results:We conducted a systematic literature search to identify publications describing controlled preclinical trials of unmodified stem cell therapy in large animal models of myocardial ischemia. Data from 82 studies involving 1415 animals showed a significant improvement in mean left ventricular ejection fraction in treated compared with control animals (8.3%, 95% confidence interval, 7.1-9.5; P<0.001). Meta-regression revealed a similar difference in left ventricular ejection fraction in autologous (8.8%, 95% confidence interval, 7.3-10.3; n=981) and allogeneic (7.3%, 95% confidence interval, 4.4-10.2, n=331; P=0.3) cell therapies. Conclusions: Autologous and allogeneic cell therapy for ischemic heart disease show a similar improvement in

show abstract

“…In another study, the intramyocardial injection of EPC in a swine model of AMI reduced the scar formation and prevented the left ventricular dysfunction after AMI, providing encouraging outcomes in favoring the application of EPCs as a potential therapy in clinical trials [105,106] (Figure 5). In the human studies performed by Li et al [108] and Lasala et al [107] it has been shown that intracoronary infusion of hEPC in patients with AMI were associated with the migration and incorporation of hEPCs in the infarcted tissue, a reduction of infarct size, and secretion of angiogenic growth factors including VEGF, SDF-1, and IGF-1, which produced more capillarity and higher transdifferentiation of cells to cardiac progenitor cardiomyocytes [107,108]. Moreover, these hEPCs also reduced apoptosis of endothelial cells and increased myocardial viability in the infarcted area [109,110].…”

Section: Clinical Translation Of Epc Therapymentioning

confidence: 99%

Vascular Regeneration by Endothelial Progenitor Cells in Health and Diseases

Nova‐Lamperti¹,

Zúñiga²,

Ormazábal³

et al. 2016

Microcirculation Revisited - From Molecules to Clinical Practice

View full text Add to dashboard Cite

Human endothelial progenitor cells (hEPCs) are adult stem cells, located in the bone marrow and peripheral blood. These cells can be differentiated into mature endothelial cells, which are involved in processes of angiogenesis and vessel regeneration. Different phenotypes and subtypes of endothelial progenitor cells (EPCs), such as early and late EPCs, have been described according to their functionality. Thus, it has been shown that early EPCs release cytokines that promote tissue regeneration and neovasculogenesis, whereas late EPC and endothelial colony forming cells (ECFCs) contribute to the formation of blood vessels and stimulate tube formation. It has been demonstrated that the number of circulating hEPC is decreased in individuals with hypercholesterolemia, hypertension, and/or diabetes. In addition, the number and the migratory activity of these cells are inversely correlated with risk factors such as hypertension, hypercholesterolemia, diabetes, and metabolic syndrome. On the other hand, the number of circulating hEPC is increased in hypoxia or acute myocardial infarction (AMI). hEPCs have been used for cell-based therapies due to their capacity to contribute in the reendothelialization of injured blood vessels and neovascularization in ischemic tissues. This chapter provides an overview of the key role of hEPC in promoting angiogenesis and their potential use for cell therapy.

show abstract

Effect of Intracoronary Infusion of Bone Marrow Mononuclear Cells or Peripheral Endothelial Progenitor Cells on Myocardial Ischemia-reperfusion Injury in Mini-swine

Cited by 10 publications

References 13 publications

Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease

Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease

Similar Effect of Autologous and Allogeneic Cell Therapy for Ischemic Heart Disease

Vascular Regeneration by Endothelial Progenitor Cells in Health and Diseases

Contact Info

Product

Resources

About